Cyn3rgy Research and Development | Gresham, OR

Research site

About

Cyn3rgy Research is a dedicated research site located in Portland, Oregon with over 25 years of clinical trial experience

Location

23331 SE Stark Stret Suite 201b, Gresham, Oregon, United States of America

Website

http://www.cyn3rgy.com/

Site insights

Top conditions

Top treatments

SPN-812

Lurasidone

Prucalopride

Viloxazine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Curt A Heiting, President

Verified by this site

Active trials

6 of 10 total trials

Locations recently updated

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20...

Enrolling

Pneumococcal Vaccines

Biological: 0.5 mL of the mid dose VAX-31

Biological: 0.5 mL of the High-PFS dose VAX-31

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germ...

Active, not recruiting

Pneumococcal Disease

Biological: 15-valent pneumococcal conjugate vaccine (PCV15)

Biological: PG4

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling

Attention-Deficit/Hyperactivity Disorder

Drug: Placebo

Drug: 100mg SPN-812

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Active, not recruiting

Attention-Deficit/Hyperactivity Disorder

Drug: SPN-812

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY)...

Active, not recruiting

Meningitis, Meningococcal

Combination Product: MenABCWY vaccine

Combination Product: Placebo

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate...

Enrolling

Pneumococcal Immunization

Biological: Vaxelis vaccine

Biological: Varivax